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Abstract
Background
Tuberculosis (TB) is difficult to diagnose in children using molecular tests, because children
have difficulty providing respiratory samples. Stool could replace sputum for diagnostic TB
testing if adequate sample processing techniques were available.
Methods
We developed a rapid method to process large volumes of stool for downstream testing by
the Xpert MTB/RIF (Xpert) TB-detection assay. The method was tested and optimized on
stool samples spiked with known numbers ofM. tuberculosis colony forming units (CFU),
and stools fromM. tuberculosis-infected cynomolgus macaques (Macaca fascicularis). Per-
formance was scored on number of positive Xpert tests, the cycle thresholds (Cts) of the
Xpert sample-processing control (SPC), and the Cts of theM. tuberculosis-specific rpoB
probes. The method was then validated on 20 confirmed TB cases and 20 controls in Dur-
ban, South Africa.
Results
The assay’s analytical limit of detection was 1,000 CFU/g of stool. As much as one gram of
spiked stool could be tested without showing increased PCR inhibition. In analytical spiking
experiments using human stool, 1g samples provided the best sensitivity compared to
smaller amounts of sample. However, in Macaques with TB, 0.6g stool samples performed
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better than either 0.2g or 1.2g samples. Testing the stool of pediatric TB suspects and con-
trols suggested an assay sensitivity of 85% (95% CI 0.6–0.9) and 84% (95% CI 0.6–0.96)
for 0.6g and 1.2g stool samples, respectively, and a specificity of 100% (95% CI 0.77–1)
and 94% (95% CI 0.7–0.99), respectively.
Conclusion
This novel approach may permit simple and rapid detection of TB using pediatric stool
samples.
Introduction
TheWorld Health Organization (WHO) estimates that over half a million new cases of child-
hood tuberculosis (TB) occur every year, with an annual mortality of up to 80,000 [1, 2]. Child-
hood TB accounts for 10–15% of the TB cases worldwide and up to 25% of cases from high TB
burden countries [3]. TB can progress very rapidly in children because of their immature
immune system [4, 5]. Rapid detection of TB in children should enable more rapid treatment
and improved outcomes.
Currently available TB tests perform poorly in children. Most pulmonary TB in adults is
diagnosed by smear, culture or molecular tests performed on expectorated sputum [6, 7]. How-
ever, children are often unable to expectorate sputum in the volume or quality needed for spu-
tum-based diagnostics. Consequently, sputum smears and cultures forMycobacterium
tuberculosis (MTB) are often negative in children with TB [8–10]. Childhood TB can also be
diagnosed by testing early morning gastric aspirates [11, 12]. However, this procedure is inva-
sive and the diagnostic yield of gastric aspirates ranges from only 20–40% [8, 12–18]. Children
are therefore often treated empirically for TB, based on clinical features, chest X-ray findings,
tuberculin skin tests, and contact with an index patient. This approach may lead to both over
and under treatment [1]. Furthermore, the lack of bacteriologic culture confirmation makes it
impossible to test for drug resistant disease. These factors create an urgent need to develop a
rapid and sensitive test that can detect TB and test for drug resistance in children [19].
Stool is a promising sample matrix for pediatric TB tests, because MTB may be swallowed
and passed into a child’s stool where it can be easily sampled. MTB is difficult to routinely cul-
ture from stool, because other rapidly growing bacteria may overgrow the slowly replicatingM.
tuberculosis bacillus. Nucleic acid based amplification tests (NAAT) can detect MTB in stool
with good sensitivity [8, 12, 20–22]. The Xpert MTB/RIF (Xpert) assay (Cepheid, Sunnyvale
CA), recommended to detect TB in sputum, has also been exploited for extra-pulmonary sam-
ples [5, 17, 22, 23]. In previous TB detection studies performed on stool, the Xpert assay
detected MTB with a sensitivity of 25–69% and a specificity of 91.7–100% [22, 24–26]. How-
ever, the stool processing protocols required centrifugation, which would not be suitable for
point of care testing in resource-limited environments. Xpert stool tests also generated unac-
ceptably large numbers of errors (13–25%) [22, 26], probably from sample clogging the Xpert
assay cartridge or due to PCR inhibition from stool components. The poor sensitivity of<50%
reported in some Xpert stool studies [24, 26] could have been due to retained PCR inhibitors,
but may also have been due to the low amounts of sample that were tested (<0.2 g) [24]. Assay
sensitivity could be increased if methods were available for testing larger quantities of stool
without introducing PCR inhibitors.
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Here, we present a novel method to process larger volumes of stool specimens for direct
detection of MTB using the Xpert assay. This approach is then validated with pediatric stool
samples from TB cases and controls.
Materials and Methods
Stool, bacterial strains and culture conditions for analytic laboratory
studies
M. tuberculosis (MTB) strain H37Rv obtained from the American Type Culture Collection
(ATCC) (Manassas, VA) was cultured and quantified by plating colony forming units (CFU)
on Middlebrook 7H10 agar plates (BD, Franklin Lakes, NJ).M. bovis BCG Pasteur strain was
used as a surrogate for MTB. Pre-quantified frozen MTB and BCG cell stocks were sonicated
or vortexed vigorously for 1 to 2 min before making serial dilutions in Middlebrook 7H9 media
(BD) in all dilution series. For analytic spiking studies, stools were obtained in the United States
from human subjects not suspected of having TB. Stools from cynomolgus (N = 5,Macaca fas-
cicularis) and rhesus macaques (N = 4,Macaca mulatta), (with active pulmonary TB induced
by intrabronchial infection of MTB strain Erdman [27, 28]) or uninfected controls from cyno-
molgus macaques (N = 5) were freshly collected or stored at 4°C after overnight transport on
ice packs.
Stool processing
Between 0.2g to 1.2g of stool, as indicated, were processed following the protocol described in
Fig 1. Two mls of a stool processing buffer (SPB), containing AL buffer (Qiagen, Valencia, CA)
and 10% Polyvinylpyrrolidone (Sigma Aldrich, St. Louis, MO), two mls of Xpert MTB/RIF
sample reagent (SR) (Cepheid), and 3 mm glass beads (Fisher Scientific, Pittsburgh, PA) were
added to the mixture. The final stool and buffer combination was mixed by snap vortexing (for
<10 seconds), incubated for 30 min at room temperature and then passed through a syringe
filter (fitted with glass wool to capture the stool debris) into a clean collection vial (Fig 1). Two
ml of this filtrate was then loaded into the sample loading chamber of an Xpert assay cartridge.
Subsequent sample processing and PCR were performed in accordance with the manufacturer's
recommendations using G3 cartridges in GeneXpert instrument (ver 4.4a).
Analytical limit of detection (LOD)
One-gram of human TB negative stool was spiked with five different concentrations ofM.
bovis BCG (10, 100, 103, 104 and 105 CFU/g) and six different concentrations of MTB strain
H37Rv cells (10, 100, 500, 103, 104 and 105 CFU/g). TB negative stool by itself was used as neg-
ative control as concentration zero in both experiments. The stool was then treated according
to the sample-processing protocol described in Fig 1 for a total of four replicates per CFU con-
centration. The LOD was defined as the lowest CFU concentration that produced 100% posi-
tive results.
Patient population and study design for clinical validation experiments
Validation studies on fresh stool samples from 20 TB positives and 20 controls were conducted
at the KwaZulu-Natal Research Institute for TB and HIV (K-RITH). Children<15 years old
were recruited between January 2013 and January 2014 from hospitals and clinics within the
Ethekwini region, Durban, KwaZulu-Natal, South Africa. Samples were taken from two groups:
TB cases, who were children confirmed to have TB by a positive Xpert MTB/RIF on induced
sputum or gastric lavage; and TB-negative controls, who were children that had symptoms or
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signs suggestive of childhood TB but who had negative Xpert MTB/RIF tests on induced spu-
tum or gastric lavage. Sputum culture was not considered as an enrollment criteria in this
study and not all subjects had both Xpert and culture tests performed. TB cases were sourced
from case file results obtained through the National Health Laboratory Services (NHLS) Gen-
eXpert laboratories, Durban and reverse traced from these documented results. TB-negative
controls were sourced from primary health care clinics or hospitals. Participants were excluded
Fig 1. Flow diagram showing how stool was processed in this study.
doi:10.1371/journal.pone.0151980.g001
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if they had been on more than five days of empiric anti-tuberculosis treatment in the past 6
months, if parental informed consent was unattainable, if child assent for participants 6 to 14
years of age was unattainable, or if they had evidence of extra-pulmonary TB. Participants were
withdrawn from the study if there was inadequate stool volume produced. Participants were
not followed up after recruitment and sample collection.
Clinical characteristics shown in Table 1 were collected by participant report and chart
reviews. TB case definitions used in Table 1 but not in the primary data analysis conformed to
national standards as follows: Definite TB disease: At least one of the signs and symptoms sug-
gestive of TB disease and microbiological confirmation of MTB [29, 30]. Probable TB disease:
At least one of the signs and symptoms suggestive of TB disease, the chest radiograph being
consistent with intra-thoracic TB disease and presence of one of the following: (a) a positive
clinical response to TB treatment, (b) documented exposure to a source case with TB disease,
or (c) immunological evidence of TB infection [29, 30]. Possible TB disease: At least one of the
signs and symptoms suggestive of TB disease and either (a) a clinical response to TB treatment,
documented exposure to a source case with TB disease or immunological evidence of TB infec-
tion, or (b) Chest radiography consistent with intra-thoracic TB disease [29, 30]. Note, that for
study purposes the standard clinical TB case definition did not include the results of molecular
tests including Xpert MTB/RIF.
Sample collection
One 5g stool sample was collected from each participant. The timing of bowel motion, sample
consistency, relationship to meals, and water intake in the previous 24 hours was noted. The
first stool passed in the day was collected for all TB cases and in 16/20 negative controls. Sam-
ples were stored at 4°C for maximum one week before testing.
Laboratory testing
All laboratory testing was performed under a sterile hood in a Biosafety laboratory 3 (BSL3)
according to standard operating procedures described in Fig 1.
Table 1. Baseline clinical findings of recruited TB cases and controls.
TB Cases1 (N = 20) TB controls2 (N = 18) P value*
Sex (male) 7 10 0.32
Age (<5years old) 8 15 0.009
HIV positive 11 5 0.11
On TB treatment 7 1 0.04
Cough >2weeks 18 5 0.0001
Other constitutional symptoms 20 5 <0.00001
Malnutrition weight-for-height <-2 z-score 7 4 0.48
Positive TB trace contact 14 2 0.0003
Deﬁnite TB3 4 0 0.1
Probable TB3 16 18 0.1
Possible TB3 0 0 NA
* 2-tailed Fisher Exact probability values
1 TB cases were deﬁned as TB suspects with either a gastric lavage or an induced sputum positive for M. tuberculosis by the Xpert MTB/RIF assay.
2 TB controls were deﬁned as TB suspects with either a gastric lavage or an induced sputum negative for M. tuberculosis by Xpert MTB/RIF assay.
3 Deﬁnitions were according to proposed international clinical case deﬁnition for intrathoracic M. tuberculosis disease [29].
doi:10.1371/journal.pone.0151980.t001
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Ethics statements
This study was approved by University of Medicine and Dentistry of New Jersey (UMDNJ)-
Institutional review board (IRB), which became the Rutgers University IRB upon the merger of
UMDNJ and Rutgers on July 1, 2013 (protocols: 2012002020 and 0120110065); by the Biomed-
ical Ethics Research Committee (BREC) of the University of KwaZulu-Natal (protocol: BE233/
11) and the KwaZulu Natal Department of Health (protocol: HRKM 072/13). The written con-
sent letter for the participants was also approved by BREC, protocol no: BE233/11 and HRKM
072/13. Participants without written consent were excluded from the study and all the docu-
ments are saved on investigators (UN and FK) computers.
The non-human primate stool samples used in this study were obtained from animals who
were being investigated for another purpose under IACUC protocol assurance number A3187-
01, and specific protocol approval numbers 13122689, 11090030, 1105870, 12060181, and
11110045. The stool samples were obtained only after they had been removed from the animal
cages and were slated to be discarded. All experimental manipulations, protocols, and care of
the animals for this parent study were approved by the University of Pittsburgh School of Med-
icine Institutional Animal Care and Use Committee (IACUC). The IACUC adheres to national
guidelines established in the Animal Welfare Act (7 U.S.C. Sections 2131–2159) and the Guide
for the Care and Use of Laboratory Animals (8th Edition) as mandated by the U.S. Public
Health Service Policy. The monkeys were housed at University of Pittsburgh Regional Biocon-
tainment Center (Animal BSL3 facility) and MO collected the stool from monkeys from the
cage pan. At the time of collection, none of the monkeys were on treatment. The authors (MJO
and JLF) had physical contact with the monkeys.
Data analysis
Standard statistical analysis (average, standard deviation and t-test) was performed using
Microsoft Excel 2000 for Windows. One-way Analysis of variance for independent or corre-
lated samples (ANOVA) was carried out to evaluate the P values using the online ANOVA cal-
culator http://faculty.vassar.edu/lowry/anova1u.html. The reference standard for the diagnosis
of TB was the Xpert induced sputum/gastric lavage results. Sensitivity was defined as the per-
cent results with a positive stool result against the GeneXpert induced sputum or gastric aspi-
rate positive cases (+/- 95% exact confidence interval). Specificity was defined as the percent
results with a negative result among control patients (+/- 95% exact confidence interval). Two-
tailed Fisher exact probability test was used to compare the TB cases to TB controls using the
online calculator http://vassarstats.net/odds2x2.html.
Results
Optimizing stool quantity
We studied how much stool sample should be added into our assay to provide the best sensitiv-
ity for TB detection [31, 32]. The goal was to introduce the maximum amount of MTB into the
assay without degrading PCR performance by introducing excess PCR inhibitors. We spiked
0.2g, 0.5g and 1g of TB negative stool with BCG at final concentrations of 1,000 CFU/g. Sam-
ples were processed using the optimized protocol (Fig 1) and tested in the Xpert assay (N = 4
for each stool weight). A delay in the cycle threshold (Ct) of the Xpert assay’s internal control
(IC) indicated PCR inhibition [33]. IC Ct values remained at an average 33±3.0 for all stool
quantities (Fig 2a), suggesting that our stool processing method effectively eliminates PCR
inhibitors in the amounts of stool that we studied. Sample processing pressures measured by
the GeneXpert instrument and reported by its normal software were not significantly affected
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Fig 2. Sample size and sensitivity. A.M. bovis BCG was spiked at 103 CFU/ml into 0.2, 0.5 and 1 g of stool (N = 4). Columns = pressure; lines = Cycle
thresholds (Cts). B. Stool samples were collected frommacaques infected withM. tuberculosis and three different amounts (0.2g, 0.6g and 1g) were tested.
The number in parenthesis indicates number of macaques tested at each volume. The shades of gray on the graph indicate the number of times the test was
performed on the same stool sample. Light gray = 1 test only; medium gray = combined data from 2 tests; dark gray = combined data from 3 tests. All the
uninfected controls tested (N = 5) were negative by this method.
doi:10.1371/journal.pone.0151980.g002
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by an increase in stool quantity (P>0.01) and were consistently below 60 PSI or approximately
one-half of the permitted pressure limit of the assay (Fig 2a). In contrast, minimum rpoB Cts
decreased to 29.8±1.8 with 1g samples compared to 32±4.4 and 35±3.4 for 0.5g and 0.2g sam-
ples, respectively (P<0.01 between 0.2g and 1.0g, Fig 2a). These results suggest that adding
increasing quantities of processed stool into the Xpert assay improves assay sensitivity for
MTB detection.
Comparing stool volumes from macaques with TB
To simulate human patients with active TB, we performed additional stool quantity ranging
studies using stools collected from nine macaques with pulmonary TB and five uninfected con-
trols. Macaque stool samples weighing 0.2g, 0.6g or 1g were tested in triplicate following the
protocol in Fig 1, (each test effectively sampled a different portion of the same stool sample) to
determine the incremental benefit of testing multiple samples. When a single stool sample was
tested for each macaque, 1/6 (17%) of the 0.2g, 4/9 (44%) of the 0.6g, and 0/6 (0%) of the 1.0g
stool samples were positive for TB (Fig 2b). When two stool samples were tested for each
macaque, 2/6 (33%), 5/9 (56%), and 2/6 (33%) of the 0.2g, 0.6g and 1.0g stool samples, respec-
tively were positive for TB. Finally, when three stool samples were tested for each macaque, 2/6
(33%) of the 0.2g stool samples, 7/9 (78%) of the 0.6g stool samples, and 2/6 (33%) of the 1.0g
stool samples were positive for TB. These data suggested that 0.6g was the optimal quantity of
stool for our assay, and that repeat testing could further improve assay sensitivity. There was
no difference in percent positive rate between the two different macaques (cynomolgus vs rhe-
sus). All the uninfected controls tested (N = 5) were negative by this method. We also observed
that macaque stool had many physical differences from the human stool. For example,
macaque stool is more pellet in form than the semi-solid consistency observed in human stool.
Analytical LOD
The assay LOD in 1g of stool was evaluated by spiking known numbers MTB CFUs into stool
specimens (Fig 3). The assay LOD was 1,000 CFU/g stool for both BCG andMTB. MTB was also
detected in 75% and 50% of stool samples spiked with 500 CFU/g and 100 CFU/g, respectively
(Fig 3B), whereas BCG was detected 66% of stool samples spiked with 100 CFU/g (Fig 3A).
Test performance on human clinical samples
Twenty TB cases and 20 TB-negative control participants were enrolled in the clinical study.
Two controls were excluded due to missing data (Fig 4). Table 1, shows relevant clinical and
laboratory characteristics of the participants. Most TB cases and controls fit the definitions
proposed by international clinical case definition for intrathoracicM. tuberculosis [29] of
“probable TB”. Sputum MGIT culture results were positive for MTB in only 4 of the 20 TB
cases, but cultures were negative in all controls. These 4 cases fit the definition of ‘definite TB’.
Tests performed on 0.6g stool samples were positive in 17/20 TB cases [sensitivity 85%
(95% CI 0.6–0.9), Table 2]. Tests performed on 1.2g stool samples were positive in 16/19 stool
TB cases [sensitivity of 84% (95% CI 0.6–0.99), Table 2] and 1/20 samples was excluded due to
probe check error. The Xpert stool assays performed on 1.2g samples detected TB in 5/6
(83.3%) participants who met our case definition by a positive gastric aspirate, and in 11/13
(84.6%) who met our case definition by a positive induced sputum. Tests performed on 0.6g
samples detected TB in 6/7 (85.7%) participants who met our case definition by a positive gas-
tric aspirate, and in 11/13 (84.6%) who met our case definition by a positive induced sputum.
The specificity of the assay performed on 0.6g stool samples was 100% [95% CI 0.80–1.00]; and
the specificity of the assay performed on 1.2g stool samples was 94% [95% CI 0.67–0.99]. Our
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assay was positive on tests of both 0.6g and 1.2g stool samples in 4/4 (100%) of participants
who were culture positive for MTB in sputum (three participants) or gastric aspirate (one
participant).
In a post hoc subgroup analysis, the stool assay at 0.6g, was positive in 8/11 (72.2%) of HIV
positive TB cases, 6/6 (100%) of HIV negative or exposed negative TB cases (HIV children
Fig 3. Analytical limit of detection. A. BCG andB.M. tuberculosis H37Rv (MTB) was spiked into stool at
final concentrations of 10 CFU/g through 105 CFU/g, processed according to our protocol, and tested using
the Xpert MTB/RIF assay.
doi:10.1371/journal.pone.0151980.g003
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exposed at birth but subsequently tested HIV negative) and 2/2 (100%) TB cases of unknown
HIV status. The assay was also positive in 6/7 (85.7%) TB cases who were on TB treatment<5
days, and in 9/13 (69.2%) TB cases who were not on anti-tuberculosis therapy. The four TB
cases with positive cultures (3 induced sputum and 1 gastric lavage) were rifampin (RIF) sensi-
tive on phenotypic testing. These four TB cases were also found to have rifampin susceptible
MTB in the stool assay. Assay performance did not appear to be affected by stool color and
consistency (semi-formed, formed, or liquid), or by water and dietary intake in the 24 hours
before stool collection.
Discussion
We have shown that a simple protocol and buffer set can be used to process stool samples so
that they can be tested for MTB with the Xpert MTB/RIF assay. Our method includes two
innovative components: a stool processing buffer (SPB), that (along with the Xpert MTB/RIF
Fig 4. Study flow diagram. Xpert stool testing of 0.6g and 1.2g volume from Xpert induced sputum (IS) and gastric washing (GW) results was performed on
above recruited participants. As indicated, repeat testing was performed on a limited stool number of samples that were initially negative.
doi:10.1371/journal.pone.0151980.g004
Table 2. Sensitivity and specificity of Xpert stool assay as tested with pediatric clinical samples.
IS/ GW-Xpert Total Sensitivity(95% CI) Speciﬁcity(95% CI)
Present Absent
Xpert-Stool 0.6 g Present 17 0 17 0.85(0.6–0.9) 1(0.77–1)
Absent 3 17 20
Xpert-Stool 1.2 g Present 16 1 17 0.84 (0.6–0.96) 0.94(0.7–0.99)
Absent 3 15 18
doi:10.1371/journal.pone.0151980.t002
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sample processing reagent—SR) inactivates PCR inhibitors and allows stool to be easily fil-
tered; and a filter configuration that permits easy filtration of the treated stool sample. We
found glass wool can be used to filter stool debris more efficiently than the other types of filter
materials tested (including cotton, Whatman filters, filter pads, gauze, and glass filter pads).
Treating stool samples with SPB and SR and then passing them through our filter as described
in Fig 1 resulted in 1 invalid (2.6% of 38 TB cases) from 0.6g and 1 invalid and 2 QC probe
check errors (7.8% of 38 TB cases) with 1.2g. Invalids are caused by a delay or an absence of
cycle threshold (Ct) from the internal control (IC), which could be due to the introduction of
PCR inhibitors from the sample. QC probe check errors are often due to abnormal signals
from the assay components within the Xpert MTB/RIF cartridge, which can have multiple
causes. In spite of these errors, this performance was significantly better than that achieved by
other stool processing methods [21, 22, 24], even though these methods were more complex,
tested smaller amounts of stool, and often required additional equipment to permit
centrifugation.
It is often difficult to achieve a firm diagnosis of tuberculosis in children [4]. For example, at
least two induced sputum samples are required to achieve the sensitivity of a single sputum
sample in adult TB suspects [18]. It is likely that pediatric TB is more paucibacillary in the
lungs compared to adults and we reasoned that paucibacillary TB would be more easily diag-
nosed by testing larger volumes of stool. Indeed, in our study of TB infected macaques, the 0.6g
stool samples were significantly more positive than the 0.2g stool samples. However, we did
not find that the 1.2g stool sample performed better than the 0.6g stool sample in our human
participants, even though tests on one 1.2g of stool did suggest that a TB negative control par-
ticipants had TB. This positive sample in a TB negative participant could represent a false posi-
tive diagnosis, or it could represent a true positive in a participant that did not meet our
diagnostic criteria for TB. This participant was treated clinically for TB but was not followed
up further.
Our study is limited by its small sample size. Our sensitivity and specificity estimates have
wide confidence intervals, and an improvement in assay performance with the larger stool size
could easily have been missed given the limited number of study participants. Finally, limited
facilities made it difficult to confirm by culture the presence of TB in most of our participants
who met our case definition of TB positive. Previous studies, however, have shown that the
Xpert MTB/RIF assay has a high positive predictive value compared to MTB cultures [34] thus,
it is likely that most of our study-defined TB cases truly had TB.
Approximately 10–20% of children from high burden countries develop TB [1, 35, 36].
Molecular diagnostic tools such as the Xpert MTB/RIF have the promise to improve diagnosis
of TB in this age group, but obtaining a good quality respiratory sample can be difficult in
children. Extra-pulmonary samples such as stool may be easier to obtain and our approach
may therefore significantly improve TB detection in children. Furthermore, not all adult TB
suspects can produce adequate sputum samples. Therefore, our approach may also be useful
in older age groups. Our modified approach to testing stool samples in the Xpert MTB/RIF
system is only one aspect of TB diagnosis that must be solved to permit this assay to be easily
used in a point of care testing environment. For example, the current GeneXpert test instru-
ment requires a laptop computer and a continuous power source. However, the recently
announced introduction of a portable, battery operated, unit that can run Xpert MTB/RIF
assays (GeneXpert Omni, http://www.cepheid.com/us/genexpert-omni) may resolve some of
the other barriers to point of care testing. In conclusion, the efficient stool sample processing
method that we developed appears to simplify TB detection in children. Larger clinical studies
are needed to evaluate the full performance parameters and the potential impact of this
methodology.
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